论文部分内容阅读
目的：探讨ｐ５３蛋白过度表达与骨肉瘤临床病理、肿瘤细胞增殖活性及预后的关系。方法：用免疫组化方法检测５０例骨肉瘤标本中ｐ５３蛋白及增殖细胞核抗原（ＰＣＮＡ）的表达。结果：５０例骨肉瘤中１６例ｐ５３蛋白阳性（３２％），ｐ５３蛋白过度表达与骨肉瘤组织学类型、组织学分级及ＰＣＮＡ分级无关。１６例ｐ５３蛋白阳性病例中，１０例在２年内死亡（６２．５％），３４例阴性病例中，１１例在２年内死亡（３２．４％）。结论：ｐ５３蛋白过度表达与骨肉瘤病人预后有关（Ｐ＜０．０５）。结果提示ｐ５３蛋白可能成为独立于ＰＣＮＡ之外的一项新的评估骨肉瘤预后的生物学指标。
Objective: To investigate the relationship between p53 protein overexpression and clinical pathology, tumor cell proliferation activity and prognosis of osteosarcoma. Methods: The expression of p53 protein and proliferating cell nuclear antigen (PCNA) in 50 specimens of osteosarcoma were detected by immunohistochemistry. Results: Of the 50 cases of osteosarcoma, 16 were positive for p53 protein (32%). The overexpression of p53 protein was not associated with the histological type, histological grade and PCNA grade of osteosarcoma. Among 16 cases of p53 protein positive cases, 10 cases died within 2 years (62.5%). In 34 negative cases, 11 cases died within 2 years (32.4%). Conclusion: The overexpression of p53 protein is associated with the prognosis of osteosarcoma patients (P<0.05). The results suggest that p53 protein may become a new biological indicator independent of PCNA to evaluate the prognosis of osteosarcoma.